Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2017 Jun 13

PMID 28604629

Citations 59

Authors

Daniel J Crona

Young E Whang

Affiliations

Soon will be listed here.

Abstract

Despite the initial efficacy of androgen deprivation in prostate cancer, virtually all patients progress to castration-resistant prostate cancer (CRPC). Androgen receptor (AR) signaling is critically required for CRPC. A new generation of medications targeting AR, such as abiraterone and enzalutamide, has improved survival of metastatic CRPC (mCRPC) patients. However, a significant proportion of patients presents with primary resistance to these agents, and in the remainder, secondary resistance will invariably develop, which makes mCRPC the lethal form of the disease. Mechanisms underlying progression to mCRPC and treatment resistance are extremely complex. AR-dependent resistance mechanisms include amplification, point mutations, expression of constitutively active splice variants, and altered intratumoral androgen biosynthesis. AR-independent resistance mechanisms include glucocorticoid receptor activation, immune-mediated resistance, and neuroendocrine differentiation. The development of novel agents, such as seviteronel, apalutamide, and EPI-001/EPI-506, as well as the identification and validation of novel predictive biomarkers of resistance, may lead to improved therapeutics for mCRPC patients.

Citing Articles

Ferroptosis in Cancer: Epigenetic Control and Therapeutic Opportunities.

Veglia Tranchese R, Battista S, Cerchia L, Fedele M Biomolecules. 2024; 14(11).

PMID: 39595619 PMC: 11592303. DOI: 10.3390/biom14111443.

The impact of androgen-induced translation in modulating androgen receptor activity.

Israel J, Marcelin L, Mehralivand S, Scholze J, Hofmann J, Stope M Biol Direct. 2024; 19(1):111.

PMID: 39529201 PMC: 11555926. DOI: 10.1186/s13062-024-00550-6.

Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study.

Hegele A, Haussermann R, Schultheis S, Skrobek L, Vink M, Hollwegs S J Cancer Res Clin Oncol. 2024; 150(9):414.

PMID: 39249593 PMC: 11384626. DOI: 10.1007/s00432-024-05928-7.

Astragaloside Ⅳ mediates the effect and mechanism of KPNB1 on biological behavior and tumor growth in prostate cancer.

Ma Q, Lu X, Tian W, Chen Y, He X Heliyon. 2024; 10(13):e33904.

PMID: 39027542 PMC: 11255569. DOI: 10.1016/j.heliyon.2024.e33904.

UBX-390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer.

Lee S, Kim H, Woo Y, Kim J, Kim H, Park J Adv Sci (Weinh). 2024; 11(33):e2400398.

PMID: 38958553 PMC: 11434238. DOI: 10.1002/advs.202400398.

References

Lee J, Phillips J, Smith B, Park J, Stoyanova T, McCaffrey E . N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016; 29(4):536-547. PMC: 4829466. DOI: 10.1016/j.ccell.2016.03.001. View

Chen C, Welsbie D, Tran C, Baek S, Chen R, Vessella R . Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004; 10(1):33-9. DOI: 10.1038/nm972. View

Karantanos T, Corn P, Thompson T . Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013; 32(49):5501-11. PMC: 3908870. DOI: 10.1038/onc.2013.206. View

Asangani I, Dommeti V, Wang X, Malik R, Cieslik M, Yang R . Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014; 510(7504):278-82. PMC: 4075966. DOI: 10.1038/nature13229. View

Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M . Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev. 2015; 41(10):884-92. DOI: 10.1016/j.ctrv.2015.08.002. View

Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

Korpal M, Korn J, Gao X, Rakiec D, Ruddy D, Doshi S . An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013; 3(9):1030-43. DOI: 10.1158/2159-8290.CD-13-0142. View

Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S . Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014; 6(254):254ra125. PMC: 4422178. DOI: 10.1126/scitranslmed.3009448. View

Myung J, Banuelos C, Garcia Fernandez J, Mawji N, Wang J, Tien A . An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013; 123(7):2948-60. PMC: 3696543. DOI: 10.1172/JCI66398. View

10.

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

11.

Boudadi K, Antonarakis E . Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol. 2016; 10(Suppl 1):1-9. PMC: 4798019. DOI: 10.4137/CMO.S34534. View

12.

Liu C, Armstrong C, Zhu Y, Lou W, Gao A . Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget. 2016; 7(22):32210-20. PMC: 5078008. DOI: 10.18632/oncotarget.8493. View

13.

Nelson P . Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol. 2011; 30(6):644-6. DOI: 10.1200/JCO.2011.39.1300. View

14.

Noonan K, North S, Bitting R, Armstrong A, Ellard S, Chi K . Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013; 24(7):1802-1807. DOI: 10.1093/annonc/mdt138. View

15.

Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L . The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer. 2014; 136(4):E27-38. DOI: 10.1002/ijc.29147. View

16.

Saporita A, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X . Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem. 2003; 278(43):41998-2005. DOI: 10.1074/jbc.M302460200. View

17.

Sun S, Sprenger C, Vessella R, Haugk K, Soriano K, Mostaghel E . Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010; 120(8):2715-30. PMC: 2912187. DOI: 10.1172/JCI41824. View

18.

Graff J, Alumkal J, Drake C, Thomas G, Redmond W, Farhad M . Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016; 7(33):52810-52817. PMC: 5288150. DOI: 10.18632/oncotarget.10547. View

19.

Balbas M, Evans M, Hosfield D, Wongvipat J, Arora V, Watson P . Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013; 2:e00499. PMC: 3622181. DOI: 10.7554/eLife.00499. View

20.

Scher H, Sawyers C . Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005; 23(32):8253-61. DOI: 10.1200/JCO.2005.03.4777. View